Bayer Pharmaceuticals streamlines Leadership Team for next phase of growth

Not intended for UK Media

• Sebastian Guth to become Chief Operating Officer (COO)
• Christine Roth to lead Global Commercialization organization

BERLIN--(BUSINESS WIRE)--Bayer’s Pharmaceutical Division is set to embark on its next phase of growth, reshaping its executive Leadership Team to become more mission-centric and value focused.

The company has been making important strides in strengthening its development portfolio and extending its capabilities through collaborations and acquisitions into breakthrough therapeutic fields such as gene therapies and cell therapies. As a next step, Bayer’s Pharmaceutical Division is focusing on renewing its top line, growing its portfolio value and leveraging a new operating model with a clear ambition of becoming a critical growth driver for Bayer.

Effective April 1, 2024, Sebastian Guth will assume the new role of Chief Operating Officer (COO) with responsibility for the commercial operations of all markets in which the company is active. In this role, Guth will work with teams across countries and regions to drive the commercial strategy to enhance customer value, maximize market opportunities, and generate revenue growth and profitability for Bayer pharmaceuticals around the world.

Guth will continue to report to Stefan Oelrich, Member of the Board of Management, Bayer AG and President of Bayer’s Pharmaceutical Division. To support the company’s strategy to substantially grow in the U.S market, he will continue to reside in the U.S.

A newly formed “Global Commercialization” organization will encompass major parts of the company’s former strategic business unit Oncology, Global Marketing and Digital & Commercial Innovation as well as parts of Medical Affairs & Pharmacovigilance.

This organization will be led by Christine Roth effective June 1, 2024. Roth, who is currently leading the company’s strategic business unit Oncology, will continue to report to Stefan Oelrich.

“Research & Development” will continue to be led by Christian Rommel while “Product Supply” will continue to be led by Holger Weintritt. Both individuals will continue to report to Stefan Oelrich as well.

“We have decided to dismantle our traditional model with functional silos and many layers of hierarchy. We are replacing it with our new operating model, which has Product and Customer Teams at its center,” said Stefan Oelrich, Member of the Board of Management, Bayer AG and President of Bayer’s Pharmaceuticals Division. “These changes within our Leadership Team reflect this new approach to realize the full potential of our growth opportunities.”

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros. For more information, go to www.bayer.com.

Find more information at https://pharma.bayer.com/
Follow us on Facebook: http://www.facebook.com/bayer

or (2024-0055e)

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.